AstraZeneca’s China partner expects to be able to make 400 mln COVID-19 vaccine doses a year


China’s Shenzhen Kangtai Biological Products said on Tuesday it had completed a facility designed to be able to produce 400 million doses of AstraZeneca’s COVID-19 vaccine per year, doubling a capacity target promised in 2020.

“Kangtai is actively pushing forward procedures for the vaccine’s clinical trial and registration in China, and has completed a manufacturing plant and started trial production,” the Shenzhen-based firm said in a press release.

The firm obtained rights to supply the AZD1222 vaccine, developed by the Anglo-Swedish drugmaker and Oxford University, in mainland China last year in return for having capacity to produce at least 200 million doses by the end of 2021.